Reid Eric, Walters Ryan W, Destache Christopher J
School of Medicine, Creighton University, Omaha, NE 68178, USA.
School of Pharmacy & Health Professions, Creighton University, Omaha, NE 68178, USA.
Antibiotics (Basel). 2021 Dec 3;10(12):1483. doi: 10.3390/antibiotics10121483.
(PA) is a leading cause of healthcare-associated infections. A variety of antibiotic classes are used in the treatment of PA infections, including beta-lactams (BLs) and fluoroquinolones (FQs), given either together in combination therapy or alone in monotherapy. A systematic review and meta-analysis were performed to evaluate the therapeutic efficacy of BL agents versus FQ agents as active, definitive monotherapy in PA infections in adults.
Comprehensive literature searches of the Medline and Scopus electronic databases, alongside hand searches of the Cochrane Database of Systematic Reviews, PubMed, and Google Scholar, were performed without a time restriction to identify studies published in English comparing BL and FQ agents given as monotherapy for PA infection in hospitalized adults for which mortality, bacteriological eradication, or clinical response was evaluated. One reviewer screened search results based on pre-defined selection criteria. Two reviewers independently assessed included studies for methodological quality using NIH assessment tools. Two fixed-effects meta-analyses were performed.
A total of 368 articles were screened, and six studies involving 338 total patients were included in the meta-analysis. Upon evaluation of methodological quality, two studies were rated good, three fair, and one poor. A meta-analysis of three studies demonstrates FQ monotherapy is associated with significantly improved survival compared to BL monotherapy for patients with PA bacteremia (OR, 3.65; 95% CI, 1.27-10.44; = 0.02). A meta-analysis of three studies demonstrates FQ monotherapy is associated with equivalent bacteriological eradication compared to BL monotherapy for PA pneumonia or skin and soft tissue infection (RD, 0.07; 95% CI, -0.09 to 0.24; = 0.39).
The meta-analyses demonstrate FQ monotherapy significantly improves survival in PA bacteremia and is associated with similar rates of bacteriological eradication in pneumonia and skin and soft tissue infection caused by PA compared to BL monotherapy. However, more research is needed to make meaningful clinical recommendations.
铜绿假单胞菌(PA)是医疗保健相关感染的主要原因。多种抗生素类别用于治疗PA感染,包括β-内酰胺类(BLs)和氟喹诺酮类(FQs),可联合使用或单独进行单一疗法。进行了一项系统评价和荟萃分析,以评估BL药物与FQ药物作为成人PA感染的活性、确定性单一疗法的治疗效果。
对Medline和Scopus电子数据库进行全面文献检索,并手工检索Cochrane系统评价数据库、PubMed和谷歌学术,检索无时间限制,以识别以英文发表的比较BL和FQ药物单一疗法治疗住院成人PA感染的研究,这些研究评估了死亡率、细菌清除率或临床反应。一名评审员根据预先定义的选择标准筛选检索结果。两名评审员使用美国国立卫生研究院评估工具独立评估纳入研究的方法学质量。进行了两项固定效应荟萃分析。
共筛选了368篇文章,荟萃分析纳入了6项研究,共338例患者。在评估方法学质量时,两项研究评为良好,三项评为中等,一项评为较差。对三项研究的荟萃分析表明,对于PA菌血症患者,与BL单一疗法相比,FQ单一疗法与生存率显著提高相关(OR,3.65;95%CI,1.27 - 10.44;P = 0.02)。对三项研究的荟萃分析表明,对于PA肺炎或皮肤及软组织感染,与BL单一疗法相比,FQ单一疗法与细菌清除率相当(RD,0.07;95%CI,-0.09至0.24;P = 0.39)。
荟萃分析表明,FQ单一疗法可显著提高PA菌血症患者的生存率,并且与PA引起的肺炎和皮肤及软组织感染的细菌清除率与BL单一疗法相似。然而,需要更多研究来提出有意义的临床建议。